Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Positive about flying? Airlines look to COVID tests that give results in minutes

Published 09/23/2020, 02:04 AM
Updated 09/23/2020, 02:31 AM
© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Frankfurt

By John Miller and Emilio Parodi

ZURICH/MILAN (Reuters) - European airlines are pinning hopes on pre-flight COVID-19 tests that deliver results as fast as pregnancy tests to help restore passengers' confidence in taking to the skies in confined spaces with shared air.

Germany's Lufthansa, at the mercy of government bailouts for survival, is in talks with Swiss drugmaker Roche over deploying so-called antigen tests, according to two people familiar with the discussions, as the airline aims to make them available next month.

Italian operator Alitalia, meanwhile, told Reuters that from Wednesday it would add two flights from Milan to Rome, to the two it is already offering from Rome to Milan, exclusively for passengers with negative tests.

The tests are administered by health authorities at the airports and included in ticket prices. If they prove popular and safe, these antigen-tested flights will be expanded to more domestic, and later international, routes, the airline said.

Unlike laboratory-based molecular tests that have been the staple of health authorities in the pandemic, antigen tests do not require machines to process. Much like pregnancy tests, they can produce results in about 15 minutes.

However the tests require an uncomfortable nasal swab and are not as accurate as the molecular, or PCR, tests. They generally produce more "false negatives" which could mean sick people could slip through the cracks and onto planes.

An increasing number are hitting the market, from companies such as Abbott Laboratories (NYSE:ABT), Becton Dickinson (NYSE:BDX) & Co and Quidel (NASDAQ:QDEL) Corp and Roche, which is rebranding antigen tests from South Korea's privately held SD Biosensor.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Airlines are pressing governments to embrace alternatives to blanket travel restrictions amid a resurgence of COVID-19 cases in Europe.

Rapid antigen tests that can be administered by non-medical staff are expected to become available in coming weeks for as little as $7 each, the head of industry body the International Air Transport Association said on Tuesday.

NEGATIVE-ONLY FLIGHTS

Despite the drawbacks of such antigen tests, carriers hope they could tip the balance in convincing people to fly.

"It is to give ... confidence, at a specific point in time, that the result is positive or negative," said Christian Paulus, a Roche research and development manager.

"The PCR remains the gold standard. Therefore if there are any questions open, or if the clinical appearance of the person who had a negative test, if the person has symptoms like a fever, then you would for sure do confirmatory testing."

Alitalia launched its "COVID Tested Flights" programme from Rome to Milan last week, and will expand it from Wednesday. Only passengers with negative COVID-19 results can board.

"So far no positive passengers have been found," said an Alitalia spokesman, adding that many chose to take the airline's antigen tests the night before the flight. Travellers can access airport-testing facilities via a preferred lane with their tickets.

The airline plans to analyse findings around the middle of October, but already expects antigen-tested flights will be expanded to domestic and later international routes. "First, we have to see how this experiment goes," the spokesman said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The pre-flight antigen tests follow a scheme in Italy where such tests were used defensively.

SD Biosensor said its tests had been deployed at Italian airports for incoming tourists, to avoid a renewed COVID-19 wave imported from infection hotspots.

'BETTER THAN QUARANTINE'

Lufthansa Chief Executive Carsten Spohr last week told employees during a townhall meeting that the airline was in talks with Roche. The drugmaker started selling the rapid tests this week, and said SD Biosensor could initially supply it with about 40 million tests per month.

The Lufthansa tests could initially go to cabin crews, a spokeswoman said, though Bjoern Becker, a senior director of product management, ground & digital services for the Lufthansa Group, said the tests could also be made available to first-class and business-class passengers.

"We think the tests would be a better option than putting somebody into quarantine," the airline spokeswoman said.

Beyond airlines, Germany is eyeing broader antigen test use from October, including in nursing homes where older patients have been hardest hit by the deadly virus.

Regulators still worry about test accuracy, which typically detect the virus 80% to 90% of the time, below the 95% rate of lab tests.

Still, some officials don't want the perfect to be the enemy of the pretty good as they pursue some semblance of economic normality.

"They're good enough," German health minister Jens Spahn said, pledging antigen tests in "significant quantities". The state of Bavaria has already ordered 10 million.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Abbott ID Now performs Pcr tests in 5”. It is just the cost. Antigen tests are much cheaper n more widely avail. Pcr tests typically cost 20usd and up, n in shortage.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.